6YID

Crystal structure of ULK2 in complex with SBI-0206965

Summary for 6YID

• Entry DOI: 10.2210/pdb6yid/pdb
• Descriptor: Serine/threonine-protein kinase ULK2, 2-({5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}oxy)-N-methylbenzene-1-carboximidic acid (3 entities in total)
• Functional Keywords: kinase, kinase inhibitor, ulk2, autophagy, chemical probe, structural genomics, structural genomics consortium, sgc, transferase
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 4
• Total formula weight: 129028.16

Authors

Chaikuad, A.,Ren, H.,Bakas, N.A.,Lambert, L.J.,Cosford, N.D.P.,Knapp, S.,Structural Genomics Consortium (SGC) (deposition date: 2020-04-01, release date: 2020-06-17, Last modification date: 2024-01-24)

Primary citation

Ren, H.,Bakas, N.A.,Vamos, M.,Chaikuad, A.,Limpert, A.S.,Wimer, C.D.,Brun, S.N.,Lambert, L.J.,Tautz, L.,Celeridad, M.,Sheffler, D.J.,Knapp, S.,Shaw, R.J.,Cosford, N.D.P.
Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
J.Med.Chem., 63:14609-14625, 2020

PubMed Abstract: Inhibition of autophagy, the major cellular recycling pathway in mammalian cells, is a promising strategy for the treatment of triple-negative breast cancer (TNBC). We previously reported SBI-0206965, a small molecule inhibitor of unc-51-like autophagy activating kinase 1 (ULK1), which is a key regulator of autophagy initiation. Herein, we describe the design, synthesis, and characterization of new dual inhibitors of ULK1 and ULK2 (ULK1/2). One inhibitor, SBP-7455 (compound ), displayed improved binding affinity for ULK1/2 compared with SBI-0206965, potently inhibited ULK1/2 enzymatic activity in vitro and in cells, reduced the viability of TNBC cells and had oral bioavailability in mice. SBP-7455 inhibited starvation-induced autophagic flux in TNBC cells that were dependent on autophagy for survival and displayed synergistic cytotoxicity with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib against TNBC cells. These data suggest that combining ULK1/2 and PARP inhibition may have clinical utility for the treatment of TNBC.

PubMed: 33200929
DOI: 10.1021/acs.jmedchem.0c00873

Experimental method

X-RAY DIFFRACTION (2.7 Å)